atrophic scar. Scar conditions and fibrosis of skin
Conditions
Interventions
Intervention 1: TCA 50%, topical, once monthly for 3 months. Intervention 2: Autologous fibroblasts (20million/mL), three times with 1-2 weeks intervals.
Treatment - Drugs
TCA 50%, topical, once monthly for 3 months.
Autologous fibroblasts (20million/mL), three times with 1-2 weeks intervals
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age more than 18 years, dissatisfaction of facial appearance, Negative pregnancy test at the screening visit, signing written informed consent, compliance with the study requirements, Healthy, non-scarred skin for biopsy Exclusion Criteria: Previous treatment with dermal filler or other method, participating in another clinical trial, History of autoimmune disease or organ transplantation, History of cancer, Active systemic infection, need to chronic antibiotic or steroidal therapy, Using systemic agents that increase bleeding or clotting, any disorder that increase bleeding or clotting, Pregnancy or breast feeding, Known allergic reaction to components of study treatment and/or study injection procedure, Excessive exposure to sun or sunburn in the post-auricular area, Patients with psychological disorders
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scar size. Timepoint: before and after the intervention. Method of measurement: Photography of scar before beginning of the study and millimeter paper. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cinical improvement of scar. Timepoint: Before the study and 3, 6, and 12 months after the beginning of study. Method of measurement: Photography of scar at each visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohamad Ali Nilforushzade
Skin Disease and Leishmaniasis Research Center (Sedigheh Tahereh)
Outcome results
None listed